Active, not recruitingNot applicableNCT03350828
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nicole Hamblett
- Principal Investigator
- Edith Zemanick, MDUniversity of Colorado, Denver
- Enrollment
- 5000 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2018 – 2026
Study locations (20)
- The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of California San Diego, La Jolla, California, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- University of Florida, Gainesville, Florida, United States
- The Nemours Children's Clinic - Orlando, Orlando, Florida, United States
- Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States
- Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, United States
- Emory University, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03350828 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS